← Browse by Condition
Medical Condition
mgmt methylated glioblastoma
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 2, Phase 3, Phase 2
ClinicalMetric tracks all active clinical trials for mgmt methylated glioblastoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Trial Phases
Phase 1 1
Phase 2 2
Phase 3 1
Top Sponsors
1 trial
1 trial
1 trial
NCT06504381 Phase 1, Phase 2
Recruiting
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
Enrollment
70 pts
Location
United States
Sponsor
University of California, San ...
NCT06419946 Phase 3
Recruiting
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Enrollment
200 pts
Location
Austria, Denmark, No...
Sponsor
Vastra Gotaland Region
NCT06649851 Phase 2
Recruiting
G-CSF After Chemo-radiation in Patients With Glioblastoma
Enrollment
60 pts
Location
United States
Sponsor
Massachusetts General Hospital
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology